StockData
Carlsmed, Inc. logo

Carlsmed, Inc. (CARL) stock

CARLNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3080% above fair value
$18.60+3.89 (+26.44%)

Close on Nov 11, 2026Market cap $507.83MP/E –Yield –

Carlsmed, Inc. grew revenue 60.4% to $71.78M over the twelve months to Sep 30, 2026. Free cash flow was -$34.92M. At the latest close the market valued the company at $507.83M.

Revenue
$71.78M
+60.4% vs. a year earlier
Operating income
-$42.33M
TTM Q3 2026
Free cash flow
-$34.92M
TTM Q3 2026
EPS, diluted
-$2.12
FY2025

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026

Valuation

Market cap
$507.83M
P/E ratio
–
Price to sales
7.08
Price to book
6.71
Dividend yield
–
Free cash flow yield
-6.88%

Fundamentals

Revenue
$71.78M
Net income
-$40.06M
EPS, diluted
-$2.12
Free cash flow
-$34.92M
Book value per share
$2.77
Diluted shares
27M

Trading

Next earnings
Feb 24, 2027 (estimated, after the close)
Previous close
$14.71
Open
$16.00
Day's range
$15.20 – $19.15
Volume
611,122
Average volume (20 days)
117,375
Index membership
Russell 2000 (since Sep 2025)
52-week range
$8.50 – $19.15
RSI (14 days)
65.3
Volatility (1 year)
75.8%
Relative volume
5.20×

On 1 of our idea list: Institutions accumulating

Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.

PeriodCARLS&P 500DifferenceCARL per yearS&P 500 per year
1 month+29.0%-2.4%+31.4 pts
3 months+35.5%-1.2%+36.6 pts
Year to date+50.6%+12.3%+38.3 pts
1 year+52.7%+12.4%+40.3 pts

Three years at a glance

Fiscal years 2023 to 2025 and trailing twelve months, USD

Revenue

$71.78M+60.4% YoY

Gross profit

$55.24M+65.1% YoY

Operating income

-$42.33M

Net income

-$40.06M

EPS, diluted

–

Free cash flow

-$34.92M
Reported periodTrailing twelve months

Press releases

Releases Carlsmed filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Carlsmed

Surgical & Medical Instruments & Apparatus

Carlsmed, Inc. is a medical technology company that develops artificial intelligence-enabled personalized solutions for spine fusion surgery. Its core offering is the aprevo Technology Platform, which integrates digital surgical planning software with custom-designed interbody implants tailored to each patient's specific spinal anatomy, alongside single-use surgical instruments. The platform addresses spinal conditions including degenerative disc disease and adult spinal deformity across both lumbar and cervical fusion procedures. Carlsmed sells its personalized implants and surgical solutions directly to hospitals and ambulatory surgical centers for use by spine surgeons.

Company profile, executives and history

Carlsmed stock: common questions

What is Carlsmed's stock price?

CARL closed at $18.60 on Nov 11, 2026, up 26.44% on the day. Over the past 52 weeks it traded between $8.50 and $19.15.

What is Carlsmed's market cap?

Carlsmed was worth $507.83M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.

What is CARL's P/E ratio?

Carlsmed lost money over fiscal 2025 (diluted EPS -$2.12), so it has no meaningful P/E ratio.

How much revenue does Carlsmed make?

Carlsmed reported revenue of $71.78M for the twelve months to Sep 30, 2026, up 60.4% from a year earlier.

Does Carlsmed pay a dividend?

No. Carlsmed has not paid a cash dividend over the last twelve months.

When does Carlsmed report earnings next?

Carlsmed is expected to report Q4 FY2026 results on Feb 24, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has CARL stock performed over the past year?

Including dividends, CARL returned +52.7% over the past year, against +12.4% for the S&P 500.

How many CARL shares are sold short?

1M shares were sold short at the latest FINRA report, 24.01% of the float, or 15.1 days of average trading volume.

Who are Carlsmed's competitors?

Companies most similar to Carlsmed by business, industry and size include SI, XTNT, APYX, LNSR, PDEX.

See a number that looks wrong?